Mitigating the Pro-inflammatory Phenotype of Obesity

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
Blood PressureDiabetesObesityInsulin ResistanceDiuretics Drug ReactionsSympathetic Nerve Activity
Interventions
DRUG

Hydrochlorothiazide 12.5Mg Tab

"Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~1. Condition/disease indication(s): Hypertension~2. Subject population: Hypertension~3. Dose(s): 25 mg/day~4. Administration: Oral~5. Dosing regimen: 12.5 mg twice per day"

DRUG

Clonidine Pill

"Will receive 4 week supply (35 days) of Clonidine Pills (0.1 mg twice/day)~Planned use in this study~1. Condition/disease indication(s): Vascular function and blood flow~2. Subject population: Hypertension~3. Dose(s): 0.1 mg (oral)~4. Administration: Oral~5. Dosing regimen: 0.1 mg twice daily by mouth"

DRUG

Placebo

Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.

Trial Locations (1)

66103

RECRUITING

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER

NCT04934228 - Mitigating the Pro-inflammatory Phenotype of Obesity | Biotech Hunter | Biotech Hunter